LTGO logo

LTGO Latigo Biotherapeutics Inc.

NASDAQ · Medical - Pharmaceuticals · Healthcare

$15.02
-1.55 (-9.35%)

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered…

Market Cap: $903.50Mwww.latigobio.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
52
3 mentions
—
60d
52
3 mentions
—
90d
47
4 mentions
—
news: 4

Analyst Ratings

Avg price target$52.25+247.9%
Low $36Median $50High $73
Current Consensus

Company Profile

CEO
Nima Farzan
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
66
Beta
0.00
Country
US
www.latigobio.com